WARPTECHNEWS · LAB

Home AI Business Tech Archive

WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

Home
Archivio
Editor's Brief
Cerca
Il tuo account
Newsletter tech/AI

Informazioni legali

Privacy Policy
Termini di servizio
Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Storia in 3 fonti

Novo Nordisk sues Hims & Hers over copycat weight-loss drugs

Shares in US company fall 16% after FDA announces investigation into unregulated medication

Raccontata da

Confronto fonti

3 prospettive sulla stessa storia

AI · summaries

ft.comStai leggendo4 mesi fa

Novo Nordisk sues Hims & Hers over copycat weight-loss drugs

Shares in US company fall 16% after FDA announces investigation into unregulated medication

cnbc.com4 mesi fa

Novo Nordisk pops 8% after Hims & Hers pulls copycat weight-loss pill

Novo Nordisk shares jumped 8% Monday after Hims & Hers said it will pull its copycat weight-loss pill off the market.

Leggi questa versione → originale

Timeline cronologica

sabato 7 febbraio 2026·ft.com
Hims & Hers abandons copycat weight-loss drug in face of FDA probe
Novo Nordisk had accused the telehealth company of breaching its patent on Wegovy
lunedì 9 febbraio 2026·ft.com
Novo Nordisk faces more gloom from price cuts in crowded anti-obesity drugs market
Danish group’s challenges mount despite winning reprieve after Hims & Hers withdraws plan to sell copycat Wegovy pill

upi.com4 mesi fa

Novo Nordisk suing Hims & Hers over ‘copycat’ weight loss drug - UPI.com

Novo Nordisk, the maker of the weight loss drug Wegovy, is suing Hims & Hers for selling a cheaper version of the drug, the company announced Monday.

Leggi questa versione → originale

lunedì 9 febbraio 2026·

cnbc.com

Novo Nordisk pops 8% after Hims & Hers pulls copycat weight-loss pill

Novo Nordisk shares jumped 8% Monday after Hims & Hers said it will pull its copycat weight-loss pill off the market.

lunedì 9 febbraio 2026·

cnbc.com

Novo Nordisk sues Hims & Hers over cheaper copycat versions of Wegovy pill, injections

Novo is asking the court to permanently ban Hims from selling compounded versions of its drugs that infringe patents, and is seeking to recover damages.

lunedì 9 febbraio 2026·

ft.com

Novo Nordisk sues Hims & Hers over copycat weight-loss drugs

Shares in US company fall 16% after FDA announces investigation into unregulated medication

lunedì 9 febbraio 2026·

upi.com

Novo Nordisk suing Hims & Hers over ‘copycat’ weight loss drug - UPI.com

Novo Nordisk, the maker of the weight loss drug Wegovy, is suing Hims & Hers for selling a cheaper version of the drug, the company announced Monday.